Patent Exclusivity Losses Push AstraZeneca's Q4 Profit Down 28%

AstraZeneca's profit declines 28% as gains in new treatments are more than offset by key patent losses in the U.S. and unfavorable foreign currency translation.

Feb 6, 2014 at 9:33AM

Global pharmaceutical giant AstraZeneca (NYSE:AZN) reported its fourth-quarter results in the wee hours of the morning today, pointing to ongoing struggles as it attempts to adapt to declining sales stemming from the loss of patent exclusivity on key drugs.

For the quarter, AstraZeneca delivered a 6% decline in revenue to $6.84 billion (a 4% decline when using constant currency figures) as GAAP EPS plummeted due to a whopping $1.76 billion one-time impairment for Bydureon. Excluding this one-time charge, adjusted EPS fell 28% to $1.23 per share.

As has been the case for years now, AstraZeneca struggled with the loss of previously key drugs to generic competition, including schizophrenia and bipolar disorder drug Seroquel, whose sales dropped 22% to $372 million on increased generic competition. Top-sellers Crestor, which treats high cholesterol levels, and Nexium, which is a heartburn medication and is set to lose its exclusivity this coming May, also witnessed a drop in revenue of 8% and 3%, respectively.

Providing some spark to its top line were sales of Symbicort, which rose 11% to $976 million, as well as anticoagulant drug Brilinta (known as Brilique in the EU), whose sales more than doubled to $92 million from $38 million in the year-ago period.

Broken down by region, U.S. revenue dropped 7%, hurt by key patent losses and higher costs created by Obamacare's health care reforms, while European and rest of world revenue both declined by 2%. China and South Korea were two notable standouts, with revenue up 21% and 17%, respectively.

Looking ahead, AstraZeneca now anticipates a low-to-mid single-digit decline in revenue at a constant exchange rate in fiscal 2014, with core EPS projected to decline by the mid-teens in terms of percentage from the $5.05 reported this morning for fiscal 2013. Furthermore, AstraZeneca is forecasting 2017 revenue will be more or less in line with the $25.7 billion reported this morning for the full-year.

link

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers